Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial

IMPORTANCE: Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options. OBJECTIVE: To evaluate the efficacy and safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients with m...

詳細記述

保存先:
書誌詳細
出版年:JAMA
主要な著者: Li, Jin, Qin, Shukui, Xu, Rui-Hua, Shen, Lin, Xu, Jianming, Bai, Yuxian, Yang, Lei, Deng, Yanhong, Chen, Zhen-dong, Zhong, Haijun, Pan, Hongming, Guo, Weijian, Shu, Yongqian, Yuan, Ying, Zhou, Jianfeng, Xu, Nong, Liu, Tianshu, Ma, Dong, Wu, Changping, Cheng, Ying, Chen, Donghui, Li, Wei, Sun, Sanyuan, Yu, Zhuang, Cao, Peiguo, Chen, Haihui, Wang, Jiejun, Wang, Shubin, Wang, Hongbing, Fan, Songhua, Hua, Ye, Su, Weiguo
フォーマット: Artigo
言語:Inglês
出版事項: American Medical Association 2018
主題:
Original Investigation
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583690/
https://ncbi.nlm.nih.gov/pubmed/29946728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.7855
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料